ADTX
HEALTHCAREAditxt Inc
$0.14+0.00 (+1.89%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ADTX Today?
No stock-specific AI insight has been generated for ADTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.10$1,979.76
$0.14
Fundamentals
Market Cap$122,100
P/E Ratio—
EPS$-9,154.64
Dividend Yield—
Dividend / Share—
ROE-7.0%
Profit Margin—
Debt / Equity—
Trading
Volume2.1M
Avg Volume (10D)—
Shares Outstanding904K
ADTX News
21 articles- Aditxt Faces Nasdaq Delisting After Extended Bid-Price NoncomplianceTipRanks·May 8, 2026
- Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer PatientsYahoo Finance·Apr 20, 2026
- Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive OfficerYahoo Finance·Mar 19, 2026
- Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy SelectionYahoo Finance·Mar 13, 2026
- Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026Yahoo Finance·Mar 5, 2026
- Wall Street Set to Open Higher Wednesday as Investors Dissect Mixed Jobs Report, Look Ahead to Thursday's Inflation DataYahoo Finance·Dec 17, 2025
- Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025Yahoo Finance·Oct 29, 2025
- BC-Most Active StocksYahoo Finance·Oct 28, 2025
- Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global MarketYahoo Finance·Oct 27, 2025
- Evofem Announces Voting Results from Special Meeting of StockholdersYahoo Finance·Oct 20, 2025
- Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media PlatformsYahoo Finance·Sep 11, 2025
- Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder MeetingYahoo Finance·Sep 9, 2025
- Aditxt’s Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030Yahoo Finance·Aug 25, 2025
- Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed LawYahoo Finance·Aug 21, 2025
- Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business UpdateYahoo Finance·Aug 14, 2025
- Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE ConferenceYahoo Finance·Aug 5, 2025
- Aditxt’s Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other DiseasesYahoo Finance·Jul 29, 2025
- Aditxt’s Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian TestYahoo Finance·Jul 24, 2025
- Aditxt to Present at Wall Street Reporter’s Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ETYahoo Finance·Jul 22, 2025
- Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary MommyYahoo Finance·Jul 15, 2025
- Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ETYahoo Finance·Jun 26, 2025
All 21 articles loaded
Price Data
Open$0.14
Previous Close$0.13
Day High$0.14
Day Low$0.13
52 Week High$1,979.76
52 Week Low$0.10
52-Week Range
$0.10$1,979.76
$0.14
Fundamentals
Market Cap$122,100
P/E Ratio—
EPS$-9,154.64
Dividend Yield—
Dividend / Share—
ROE-7.0%
Profit Margin—
Debt / Equity—
Trading
Volume2.1M
Avg Volume (10D)—
Shares Outstanding904K
About Aditxt Inc
Aditxt Inc. is an innovative biotechnology firm dedicated to transforming healthcare through its proprietary immune modulation and personalized medicine platform. The company focuses on enhancing immune responses to effectively address chronic diseases and allergies, ultimately improving patient outcomes. With a robust pipeline of therapeutic candidates supported by extensive research and strategic collaborations, Aditxt is poised to become a leader in the burgeoning field of immune-based therapies. By prioritizing scientific advancements and patient-centered solutions, Aditxt aims to significantly impact the future of immunology and the broader healthcare landscape.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—